optiPRM: A Targeted Immunopeptidomics LC-MS Workflow With Ultra-High Sensitivity for the Detection of Mutation-Derived Tumor Neoepitopes From Limited Input Material
Molecular & Cellular Proteomics · 2024-09 · 23 (9) · 100825
DOI: 10.1016/j.mcpro.2024.100825 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2024-09. Verfasst von Mogjiborahman Salek und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunotherapy and Immunoprevention, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany; Molecular Vaccine Design, Germa…. Hauptthemen laut MEDLINE: Workflow, Mutation, Proteomics. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Personalized cancer immunotherapies such as therapeutic vaccines and adoptive transfer of T cell receptor-transgenic T cells rely on the presentation of tumor-specific peptides by human leukocyte antigen class I molecules to cytotoxic T cells. Such neoepitopes can for example arise from somatic mutations and their identification is crucial for the rational design of new therapeutic interventions. Liquid chromatography mass spectrometry (LC-MS)-based immunopeptidomics is the only method to directly prove actual peptide presentation and we have developed a parameter optimization workflow to tune targeted assays for maximum detection sensitivity on a per peptide basis, termed optiPRM. Optimization of collision energy using optiPRM allows for the improved detection of low abundant peptides that are very hard to detect using standard parameters. Applying this to immunopeptidomics, we detected a neoepitope in a patient-derived xenograft from as little as 2.5 × 106 cells input. Application of the workflow on small patient tumor samples allowed for the detection of five mutation-derived neoepitopes in three patients. One neoepitope was confirmed to be recognized by patient T cells. In conclusion, optiPRM, a targeted MS workflow reaching ultra-high sensitivity by per peptide parameter optimization, makes the identification of actionable neoepitopes possible from sample sizes usually available in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Immunotherapy and Immunoprevention, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany; Molecular Vaccine Design, German Center for Infection Research (DZIF), Partner Site Heidelberg, Heide…
- Antigen Presentation and T/NK Cell Activation Group, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany; Department of Medical Oncology, National Center for Tumor Diseases (NCT), NCT Heidelberg, a Part…
- Department of Medical Oncology, National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Applied Tumor Immun…
- Department of Medical Oncology, National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and University Hospital Heidelberg, Heidelberg, Germany.
- Faculty of Biosciences, Heidelberg University, Heidelberg, Germany; Immune Monitoring Unit, National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ and University Hospital Heidelberg, Heidel…
- T Cell Discovery Platform, Helmholtz Institute for Translational Oncology (HI-TRON) Mainz - A Helmholtz Institute of the DKFZ, Mainz, Germany.
Zitieren
APA
Salek, M., Förster, J. D., Becker, J. P., Meyer, M., Charoentong, P., Lyu, Y., Lindner, K., Lotsch, C., Volkmar, M., Momburg, F., Poschke, I., Fröhling, S., Schmitz, M., Offringa, R., Platten, M., Jäger, D., Zörnig, I., & Riemer, A. B. (2024). optiPRM: A Targeted Immunopeptidomics LC-MS Workflow With Ultra-High Sensitivity for the Detection of Mutation-Derived Tumor Neoepitopes From Limited Input Material. Molecular & Cellular Proteomics, 23(9), 100825. https://doi.org/10.1016/j.mcpro.2024.100825
Vancouver
Salek M, Förster JD, Becker JP, Meyer M, Charoentong P, Lyu Y, et al. optiPRM: A Targeted Immunopeptidomics LC-MS Workflow With Ultra-High Sensitivity for the Detection of Mutation-Derived Tumor Neoepitopes From Limited Input Material. Molecular & Cellular Proteomics. 2024;23(9):100825. doi:10.1016/j.mcpro.2024.100825
BibTeX
@article{Salek2024,
author = {Salek, Mogjiborahman and Förster, Jonas D and Becker, Jonas P and Meyer, Marten and Charoentong, Pornpimol and Lyu, Yanhong and Lindner, Katharina and Lotsch, Catharina and Volkmar, Michael and Momburg, Frank and Poschke, Isabel and Fröhling, Stefan and Schmitz, Marc and Offringa, Rienk and Platten, Michael and Jäger, Dirk and Zörnig, Inka and Riemer, Angelika B},
title = {optiPRM: A Targeted Immunopeptidomics LC-MS Workflow With Ultra-High Sensitivity for the Detection of Mutation-Derived Tumor Neoepitopes From Limited Input Material},
journal = {Molecular & Cellular Proteomics},
year = {2024},
volume = {23},
number = {9},
pages = {100825},
doi = {10.1016/j.mcpro.2024.100825}
}
EUVIMED